Abstract
Purpose: EBV-latent membrane protein-1 (LMP-1) is often expressed in Hodgkin and Reed-Sternberg (HRS) cells of classical Hodgkin's lymphoma (cHL), but its clinical significance is controversial. We correlated LMP-1 with presenting features, including serum interleukin 10 levels and clinical outcome. Experimental Design: Patients were eligible if they had biopsy-proven cHL, were untreated, HIV-1 negative, and had available archival tissue. LMP-1 expression was determined by immunohistochemistry. Results: We identified 577 patients with cHL with a median age of 30 years, 55% of whom were male. LMP-1 was expressed in HRS cells of 124 patients (21%) and was detected in 78 of 461 (17%) patients with nodular sclerosis compared with 44 of 112 (39%) with mixed cellularity (P <0.001 by Fisher's exact test). Patients with tumors with LMP-1-positive HRS cells had higher serum interleukin 10 levels (P = 0.009 by Mann-Whitney test). For the 303 patients treated with doxorubicin, bleomycin, vinblastine, and dacarbazine or equivalent regimens, the 5-year failure-free survival (FFS) for those with LMP-1-positive tumors was 74% compared with 81% for those with LMP-1-negative tumors (P = 0.23, by log-rank test). Overall survival (OS) at 5 years for patients with LMP-1-positive tumors was 90 versus 91% for patients with LMP-1-negative tumors (P = 0.8 by log-rank test). Expression of LMP-1 was not associated with different FFS and OS in patients treated with other regimens or with radiotherapy alone. Conclusions: LMP-1 was expressed by HRS cells in 21% of cHL and correlated with mixed cellularity type and higher serum interleukin 10 levels. The presence of LMP-1 was not associated with FFS or OS in uniformly treated patients.
| Original language | English |
|---|---|
| Pages (from-to) | 2114-2120 |
| Number of pages | 7 |
| Journal | Clinical Cancer Research |
| Volume | 9 |
| Issue number | 6 |
| Publication status | Published - Jun 1 2003 |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Expression of Epstein-Barr virus latent membrane protein-1 in Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma : Associations with presenting features, serum interleukin 10 levels, and clinical outcome. / Herling, Marco; Rassidakis, George Z.; Medeiros, L. Jeffrey; Vassilakopoulos, Theodoros P.; Kliche, Kay Oliver; Nadali, Gianpaolo; Viviani, Simonetta; Bonfante, Valeria; Giardini, Roberto; Chilosi, Marco; Kittas, Christos; Gianni, Alessandro M.; Bonadonna, Gianni; Pizzolo, Giovanni; Pangalis, Gerassimos A.; Cabanillas, Fernando; Sarris, Andreas H.
In: Clinical Cancer Research, Vol. 9, No. 6, 01.06.2003, p. 2114-2120.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Expression of Epstein-Barr virus latent membrane protein-1 in Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma
T2 - Associations with presenting features, serum interleukin 10 levels, and clinical outcome
AU - Herling, Marco
AU - Rassidakis, George Z.
AU - Medeiros, L. Jeffrey
AU - Vassilakopoulos, Theodoros P.
AU - Kliche, Kay Oliver
AU - Nadali, Gianpaolo
AU - Viviani, Simonetta
AU - Bonfante, Valeria
AU - Giardini, Roberto
AU - Chilosi, Marco
AU - Kittas, Christos
AU - Gianni, Alessandro M.
AU - Bonadonna, Gianni
AU - Pizzolo, Giovanni
AU - Pangalis, Gerassimos A.
AU - Cabanillas, Fernando
AU - Sarris, Andreas H.
PY - 2003/6/1
Y1 - 2003/6/1
N2 - Purpose: EBV-latent membrane protein-1 (LMP-1) is often expressed in Hodgkin and Reed-Sternberg (HRS) cells of classical Hodgkin's lymphoma (cHL), but its clinical significance is controversial. We correlated LMP-1 with presenting features, including serum interleukin 10 levels and clinical outcome. Experimental Design: Patients were eligible if they had biopsy-proven cHL, were untreated, HIV-1 negative, and had available archival tissue. LMP-1 expression was determined by immunohistochemistry. Results: We identified 577 patients with cHL with a median age of 30 years, 55% of whom were male. LMP-1 was expressed in HRS cells of 124 patients (21%) and was detected in 78 of 461 (17%) patients with nodular sclerosis compared with 44 of 112 (39%) with mixed cellularity (P <0.001 by Fisher's exact test). Patients with tumors with LMP-1-positive HRS cells had higher serum interleukin 10 levels (P = 0.009 by Mann-Whitney test). For the 303 patients treated with doxorubicin, bleomycin, vinblastine, and dacarbazine or equivalent regimens, the 5-year failure-free survival (FFS) for those with LMP-1-positive tumors was 74% compared with 81% for those with LMP-1-negative tumors (P = 0.23, by log-rank test). Overall survival (OS) at 5 years for patients with LMP-1-positive tumors was 90 versus 91% for patients with LMP-1-negative tumors (P = 0.8 by log-rank test). Expression of LMP-1 was not associated with different FFS and OS in patients treated with other regimens or with radiotherapy alone. Conclusions: LMP-1 was expressed by HRS cells in 21% of cHL and correlated with mixed cellularity type and higher serum interleukin 10 levels. The presence of LMP-1 was not associated with FFS or OS in uniformly treated patients.
AB - Purpose: EBV-latent membrane protein-1 (LMP-1) is often expressed in Hodgkin and Reed-Sternberg (HRS) cells of classical Hodgkin's lymphoma (cHL), but its clinical significance is controversial. We correlated LMP-1 with presenting features, including serum interleukin 10 levels and clinical outcome. Experimental Design: Patients were eligible if they had biopsy-proven cHL, were untreated, HIV-1 negative, and had available archival tissue. LMP-1 expression was determined by immunohistochemistry. Results: We identified 577 patients with cHL with a median age of 30 years, 55% of whom were male. LMP-1 was expressed in HRS cells of 124 patients (21%) and was detected in 78 of 461 (17%) patients with nodular sclerosis compared with 44 of 112 (39%) with mixed cellularity (P <0.001 by Fisher's exact test). Patients with tumors with LMP-1-positive HRS cells had higher serum interleukin 10 levels (P = 0.009 by Mann-Whitney test). For the 303 patients treated with doxorubicin, bleomycin, vinblastine, and dacarbazine or equivalent regimens, the 5-year failure-free survival (FFS) for those with LMP-1-positive tumors was 74% compared with 81% for those with LMP-1-negative tumors (P = 0.23, by log-rank test). Overall survival (OS) at 5 years for patients with LMP-1-positive tumors was 90 versus 91% for patients with LMP-1-negative tumors (P = 0.8 by log-rank test). Expression of LMP-1 was not associated with different FFS and OS in patients treated with other regimens or with radiotherapy alone. Conclusions: LMP-1 was expressed by HRS cells in 21% of cHL and correlated with mixed cellularity type and higher serum interleukin 10 levels. The presence of LMP-1 was not associated with FFS or OS in uniformly treated patients.
UR - http://www.scopus.com/inward/record.url?scp=0037838706&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037838706&partnerID=8YFLogxK
M3 - Article
C2 - 12796376
AN - SCOPUS:0037838706
VL - 9
SP - 2114
EP - 2120
JO - Clinical Cancer Research
JF - Clinical Cancer Research
SN - 1078-0432
IS - 6
ER -